LONG-TERM SURVIVAL AFTER RADIOTHERAPY ALONE: RADIATION THERAPY ONCOLOGY GROUP PROSTATE CANCER TRIALS
Authors:
- Jiandong LuJLJiandong Lu
- Miljenko V. PilepichMPMiljenko V. Pilepich
- Sucha O. AsbellSASucha O. Asbell
- Mohammed MohiuddinMMMohammed Mohiuddin
- Roger TerryRTRoger Terry
- David GrignonDGDavid Grignon
- 1 March 1999
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 161 (3) , 864-868
Abstract
We assess the relative importance of the several pretreatment characteristics in predicting death from prostate cancer in patients treated with curative intent with external beam radiotherapy alone. Patients entered on 4 prospective phase III randomized trials conducted by the Radiation Therapy Oncology Group between 1975 and 1992 were selected for this analysis if they were deemed evaluable and eligible for the trial, they had received no hormonal therapy with initial treatment and followup information was available. A disease specific survival event was declared if death was certified as due to prostate cancer, complications of treatment or unknown causes with clinically active malignancy. Median followup for patients treated on early and late studies exceeded 11 and 6 years, respectively. Most of the patients (1,557) had tumors clinically staged as T3 (59%), and 87 (36%) with clinically staged T1-2 tumors had pathologically positive lymph nodes. On multivariate analysis Gleason score, clinical stage and nodal status were associated with a less favorable overall and disease specific survival, whereas others factors, such as age and race, were not. A Gleason score of 8 to 10 was associated with a high risk of dying of prostate cancer in the first 5 years (risk ratio 20.0, p = 0.0001). The 10-year disease specific survival for patients with a Gleason score of 2 to 5, 6 to 7 and 8 to 10 was 87, 75 and 44%, respectively, following radiotherapy. Based on published reports these rates were higher than expected with observation alone. In the first 10 years Gleason score was the single most important predictor of death. Gleason score should be incorporated into the current clinical staging system.Keywords
This publication has 22 references indexed in Scilit:
- 1007 The need for central pathology tumor grading in prostate cancer using radiation therapy oncology group(RTOG) 8531International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1997
- Need for Hospital Care and Palliative Treatment for Prostate Cancer Treated with Noncurative IntentJournal of Urology, 1995
- Long-term Survival and Mortality in Prostate Cancer Treated with Noncurative IntentJournal of Urology, 1995
- Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the radiation therapy oncology groupUrology, 1995
- Proportional hazards tests and diagnostics based on weighted residualsBiometrika, 1994
- Results of Conservative Management of Clinically Localized Prostate CancerNew England Journal of Medicine, 1994
- A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team1993
- High 10-year survival rate in patients with early, untreated prostatic cancer1992
- Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1988
- Prognostic factors in carcinoma of the prostate— analysis of rtog study 75-06International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1987